Jacobs Levy Equity Management
RLAY icon

Jacobs Levy Equity Management’s Relay Therapeutics RLAY Stock Holding History

Jacobs Levy Equity Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,675,403
Closed -$13.9M – 1032
2024
Q1 		$13.9M Sell
1,675,403
-8,896
-0.5% -$86.8K 0.06% 253
2023
Q4 		$18.5M Buy
1,684,299
+1,349,228
+403% +$11.4M 0.09% 217
2023
Q3 		$2.82M Buy
+335,071
New +$3.6M 0.02% 501

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Jacobs Levy Equity Management's RLAY Position: Q2 2024 in Review

Jacobs Levy Equity Management sold out of Relay Therapeutics (RLAY) in Q2 2024, closing a stake of 1,675,403 shares — an estimated $13.9M sold.

Jacobs Levy Equity Management first reported a position in RLAY in Q3 2023 and held it in 3 quarters. The position peaked at $18.5M in Q4 2023. 178 funds tracked by Wall St. Rank hold RLAY as of Q2 2024.

  • Jacobs Levy Equity Management reported no remaining Relay Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 1,675,403 Relay Therapeutics shares in Q2 2024, an estimated $13.9M.
  • Jacobs Levy Equity Management first reported a position in Relay Therapeutics in Q3 2023 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Relay Therapeutics position peaked at $18.5M in Q4 2023.
  • 178 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2024, filed 14 Aug 2024.